Essential Thrombocythemia | Treatment Algorithms: Claims Data Analysis | US | 2021
Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and prognoses based on their age and clinical findings. Although most patients respond adequately to first-line treatments, a high unmet need exists for second-line agents that can be used in patients who do not respond to or cannot tolerate first-line therapy.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ET patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ET patients?
- How has anagrelide (Agrylin) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of ET patients receive drug therapy after diagnosis and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
- What percentage of ET patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution Enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key drugs: Aspirin, hydroxyurea, peg-IFN, anagrelide, ruxolitinib
